JP2019531352A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019531352A5 JP2019531352A5 JP2019541688A JP2019541688A JP2019531352A5 JP 2019531352 A5 JP2019531352 A5 JP 2019531352A5 JP 2019541688 A JP2019541688 A JP 2019541688A JP 2019541688 A JP2019541688 A JP 2019541688A JP 2019531352 A5 JP2019531352 A5 JP 2019531352A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- administered
- frequency
- nanoparticles
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims description 35
- 239000002105 nanoparticle Substances 0.000 claims description 32
- 208000026278 immune system disease Diseases 0.000 claims description 16
- 229920006318 anionic polymer Polymers 0.000 claims description 12
- YBHILYKTIRIUTE-UHFFFAOYSA-N berberine Chemical compound C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 YBHILYKTIRIUTE-UHFFFAOYSA-N 0.000 claims description 12
- 229940093265 berberine Drugs 0.000 claims description 12
- QISXPYZVZJBNDM-UHFFFAOYSA-N berberine Natural products COc1ccc2C=C3N(Cc2c1OC)C=Cc4cc5OCOc5cc34 QISXPYZVZJBNDM-UHFFFAOYSA-N 0.000 claims description 12
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 10
- 229920000669 heparin Polymers 0.000 claims description 10
- 229960002897 heparin Drugs 0.000 claims description 10
- 229920001661 Chitosan Polymers 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 8
- 206010020751 Hypersensitivity Diseases 0.000 claims description 6
- 230000007815 allergy Effects 0.000 claims description 6
- 235000014571 nuts Nutrition 0.000 claims description 6
- 229920000642 polymer Polymers 0.000 claims description 6
- 150000003836 berberines Chemical class 0.000 claims description 5
- 208000004262 Food Hypersensitivity Diseases 0.000 claims description 4
- 206010016946 Food allergy Diseases 0.000 claims description 4
- 208000026935 allergic disease Diseases 0.000 claims description 4
- 235000020932 food allergy Nutrition 0.000 claims description 4
- 230000001404 mediated effect Effects 0.000 claims description 4
- 229920001282 polysaccharide Polymers 0.000 claims description 4
- 239000005017 polysaccharide Substances 0.000 claims description 4
- 150000004804 polysaccharides Chemical class 0.000 claims description 4
- 229940045110 chitosan Drugs 0.000 claims description 3
- 244000144725 Amygdalus communis Species 0.000 claims description 2
- 244000226021 Anacardium occidentale Species 0.000 claims description 2
- 244000105624 Arachis hypogaea Species 0.000 claims description 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 2
- 208000015943 Coeliac disease Diseases 0.000 claims description 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 2
- 208000011231 Crohn disease Diseases 0.000 claims description 2
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 2
- 108010068370 Glutens Proteins 0.000 claims description 2
- 208000009329 Graft vs Host Disease Diseases 0.000 claims description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 2
- 241000758791 Juglandaceae Species 0.000 claims description 2
- 241000208467 Macadamia Species 0.000 claims description 2
- 201000004681 Psoriasis Diseases 0.000 claims description 2
- 206010039085 Rhinitis allergic Diseases 0.000 claims description 2
- 206010052779 Transplant rejections Diseases 0.000 claims description 2
- 241000209140 Triticum Species 0.000 claims description 2
- 235000021307 Triticum Nutrition 0.000 claims description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 2
- 230000000172 allergic effect Effects 0.000 claims description 2
- 201000010105 allergic rhinitis Diseases 0.000 claims description 2
- 235000020224 almond Nutrition 0.000 claims description 2
- 229940126575 aminoglycoside Drugs 0.000 claims description 2
- 125000000129 anionic group Chemical group 0.000 claims description 2
- 229920001586 anionic polysaccharide Polymers 0.000 claims description 2
- 150000004836 anionic polysaccharides Chemical group 0.000 claims description 2
- 208000006673 asthma Diseases 0.000 claims description 2
- 201000008937 atopic dermatitis Diseases 0.000 claims description 2
- 208000010668 atopic eczema Diseases 0.000 claims description 2
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 2
- 235000020113 brazil nut Nutrition 0.000 claims description 2
- 235000020226 cashew nut Nutrition 0.000 claims description 2
- 235000013365 dairy product Nutrition 0.000 claims description 2
- 239000002158 endotoxin Substances 0.000 claims description 2
- 235000013332 fish product Nutrition 0.000 claims description 2
- 235000021312 gluten Nutrition 0.000 claims description 2
- 208000024908 graft versus host disease Diseases 0.000 claims description 2
- 229920006008 lipopolysaccharide Polymers 0.000 claims description 2
- 239000002245 particle Substances 0.000 claims description 2
- 235000020232 peanut Nutrition 0.000 claims description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 2
- 235000015170 shellfish Nutrition 0.000 claims description 2
- 208000011580 syndromic disease Diseases 0.000 claims description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 2
- 235000020234 walnut Nutrition 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 44
- 238000000034 method Methods 0.000 description 44
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662408541P | 2016-10-14 | 2016-10-14 | |
| US62/408,541 | 2016-10-14 | ||
| PCT/US2017/056822 WO2018071917A1 (en) | 2016-10-14 | 2017-10-16 | Treatment of immunological disease using berberine nanoparticles |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019531352A JP2019531352A (ja) | 2019-10-31 |
| JP2019531352A5 true JP2019531352A5 (enExample) | 2020-11-26 |
Family
ID=61906052
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019541688A Pending JP2019531352A (ja) | 2016-10-14 | 2017-10-16 | ベルベリンナノ粒子を用いた免疫疾患の治療 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US11351157B2 (enExample) |
| EP (1) | EP3525760A4 (enExample) |
| JP (1) | JP2019531352A (enExample) |
| CN (1) | CN110290780A (enExample) |
| AU (1) | AU2017342558A1 (enExample) |
| CA (1) | CA3039587A1 (enExample) |
| WO (1) | WO2018071917A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2020410909A1 (en) * | 2019-12-23 | 2022-07-14 | Prota Therapeutics Pty Ltd | Pharmaceutical compositions |
| IL299009A (en) * | 2020-06-11 | 2023-02-01 | Univ Columbia | Methods and compositions for preventing and treating myopia with berberine, a berberidaceaen alkaloid, and derivatives thereof |
| CN114460301B (zh) * | 2021-12-28 | 2024-11-29 | 上海睿康生物科技有限公司 | 一种测定血清中肌酸激酶同工酶含量的检测试剂盒 |
| CN114487444B (zh) * | 2021-12-28 | 2024-09-20 | 上海睿康生物科技有限公司 | 一种测定血清中抗穆勒氏管激素含量的检测试剂盒 |
| CN114306640A (zh) * | 2022-01-27 | 2022-04-12 | 南方医科大学南方医院 | 一种增加小檗碱溶解度的方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007031812A1 (en) * | 2005-09-16 | 2007-03-22 | Medipol Sa | Chitosan-based particles |
| EP1774971A1 (en) * | 2005-10-14 | 2007-04-18 | Advanced in Vitro Cell Technologies, S.L. | Chitosan and heparin nanoparticles |
| CA2636139A1 (en) * | 2005-12-14 | 2007-06-21 | Cytos Biotechnology Ag | Immunostimulatory nucleic acid packaged particles for the treatment of hypersensitivity |
| US8802076B2 (en) * | 2010-10-04 | 2014-08-12 | Duke University | Compositions and methods for modulating an immune response |
| EP3760223A1 (en) * | 2013-04-03 | 2021-01-06 | N-Fold Llc | Nanoparticle composition for desensitizing a subject to peanut allergens |
| WO2014179528A2 (en) * | 2013-05-01 | 2014-11-06 | Brown Dennis M | Compositions and methods to improve the therapeutic benefit of suboptimally administered chemical compounds including substituted naphthalimides such as amonafide for the treatment of immunological, metabolic, infectious, and benign or neoplastic hyperproliferative disease conditions |
| US9572831B2 (en) * | 2013-10-29 | 2017-02-21 | Shaker A. Mousa | Composition and method for sulfated non-anticoagulant low molecular weight heparins in cancer and tumor metastasis |
| US10500169B2 (en) * | 2014-09-17 | 2019-12-10 | Xiu-Min Li | Supression of IgE production by compounds derived from traditional chinese medicine |
-
2017
- 2017-10-16 WO PCT/US2017/056822 patent/WO2018071917A1/en not_active Ceased
- 2017-10-16 CN CN201780077346.3A patent/CN110290780A/zh active Pending
- 2017-10-16 US US16/341,582 patent/US11351157B2/en active Active
- 2017-10-16 EP EP17859782.9A patent/EP3525760A4/en not_active Withdrawn
- 2017-10-16 JP JP2019541688A patent/JP2019531352A/ja active Pending
- 2017-10-16 AU AU2017342558A patent/AU2017342558A1/en not_active Abandoned
- 2017-10-16 CA CA3039587A patent/CA3039587A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019531352A5 (enExample) | ||
| Piqué et al. | Xyloglucan, a plant polymer with barrier protective properties over the mucous membranes: an overview | |
| Vetvicka et al. | Glucan supplementation enhances the immune response against an influenza challenge in mice | |
| Rajendran et al. | Polysaccharides from marine macroalga, Padina gymnospora improve the nonspecific and specific immune responses of Cyprinus carpio and protect it from different pathogens | |
| HK1246654A1 (zh) | 具有有效表位显示的病毒样颗粒 | |
| JP2016530265A5 (enExample) | ||
| NZ741082A (en) | C4-modified oleanolic acid derivatives for inhibition of il-17 and other uses | |
| RU2018139655A (ru) | Бифидобактерии для увеличения безжировой массы тела | |
| JP2019517541A5 (enExample) | ||
| Zheng et al. | Novel mechanistic insights underlying fungal allergic inflammation | |
| Camargo Jr | Vitamin D, acute respiratory infection, and asthma/chronic obstructive pulmonary disease | |
| Calvete et al. | Child-to-parent violence: Frequency and reasons for aggressions against parents | |
| JP2023522687A (ja) | 筋萎縮を軽減および／または筋肉再生を促進する方法 | |
| EA201591871A1 (ru) | Фармацевтическая композиция, содержащая будесонид и формотерол | |
| Pascoe et al. | Blood eosinophil counts as markers of response to inhaled corticosteroids in COPD?–Authors' reply | |
| WO2017142368A3 (ko) | 알레르기성 또는 염증성 피부질환의 예방 또는 치료용 조성물 | |
| Born | A pragmatic approach to immunity & respiratory viral infections | |
| van Leeuwen | Consequences of the REDOXS and METAPLUS Trials: the end of an era of glutamine and antioxidant supplementation for critically ill patients? | |
| Afshar | Medicinal Properties of Precious Stones Reflected in Ancient Medical and Literary Texts | |
| Amison et al. | Thrombocytopenia Impairs Host Defence In A Murine Model Of Pulmonary Infection With psuedomonas AerugINOSa | |
| Alam | The amazing mast cell | |
| Sivakumar et al. | Identification of new snake venom zinc Metalloproteinase inhibitor using docking studies from Plectanthus amboinicus | |
| Verleden et al. | Common indications and side effects of azithromycin | |
| WO2016197944A1 (zh) | 无标题 | |
| Cai et al. | B50 OCCUPATIONAL AND ENVIRONMENTAL EXPOSURES AND EFFECTS: INTERDISCIPLINARY SESSION: Secondhand Smoke Exposure Impairs Host Defense Against Gram-Negative Infection |